ProQR Announces Annual Meeting of Shareholders to be Held

Announces Annual Meeting of Shareholders to be Held May 17, 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 - ProQR

Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary

Axiomer RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Wednesday,

May 17, 2023 at 16:00 CET (10:00am EDT) at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands.

All relevant documents and information for the meeting, including the

notice and agenda and explanatory notes, are or will be made available in the "Investors & Media" section of ProQR's

website (www.proqr.com) under "Financials and filings" and then

"Shareholder meeting". The documents will also be made available on the SEC's website at www.sec.gov.

Shareholders that wish to attend should register as described in the notice and agenda.

As part of the AGM, the Company highlights the following Supervisory Board

ProQR is pioneering a next-generation RNA base editing technology called

Axiomer , which could potentially yield a new class of medicines for diverse types of diseases. Axiomer

"Editing Oligonucleotides", or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using

molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed

to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA - an Inosine is translated

as a Guanosine (G) - correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression,

or altering a protein so that it will have a new function that helps prevent or treat disease.

ProQR Therapeutics is dedicated to changing lives through the creation

of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer , which uses a cell's

own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression

and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary

RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements

other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate,"

"believe," "could," "estimate," "expect," "goal," "intend," "look forward

to", "may," "plan," "potential," "predict," "project," "should," "will,"

"would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business,

technology, strategy, our Axiomer platform, and our product candidates and their therapeutic potential. Forward-looking statements are

based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our

actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without

limitation, the risks, uncertainties and other factors in our

filings made with the Securities and Exchange Commission, including certain

sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of

preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our preclinical

and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability

of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract

manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential

for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results

of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical

programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration

with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy

concerns that could emerge as new data are generated in research and development; and general business, operational, financial and accounting

risks, and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should

not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements,

even if new information becomes available in the future, except as required by law.

For ProQR Therapeutics N.V.

ProQR Therapeutics N.V.